Denali Therapeutics/$DNLI
About Denali Therapeutics
Ticker
Industry
Employees
DNLI Metrics
$2.8B
-
-$2.73
1.39
-
Price and volume
Market cap
$2.8B
Beta
1.39
52-week high
$31.56
52-week low
$14.56
Average daily volume
905K
Financial strength
Current ratio
9.976
Quick ratio
9.621
Long term debt to equity
3.374
Total debt to equity
3.983
Interest coverage (TTM)
-5,125.04%
Management effectiveness
Return on assets (TTM)
-23.81%
Return on equity (TTM)
-35.09%
Valuation
Price to book
2.14
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
-8.161
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
198.65%
3-year earnings per share growth (CAGR)
126.24%
What the Analysts think about DNLI
Analyst Ratings
DNLI Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
DNLI Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
DNLI News
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics ALS drug fails in mid-stage trial
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
FAQs
What’s the current market cap for Denali Therapeutics stock?
What is the P/E ratio for Denali Therapeutics stock?
Does Denali Therapeutics stock pay dividends?
No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Denali Therapeutics dividend payment date?
Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Denali Therapeutics?
Denali Therapeutics (DNLI) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.